Relationship between serum infliximab levels and acute uveitis attacks in patients with Behçet disease

British Journal of Ophthalmology

Volumn 95, Issue 4, 2011, Pages 549-552

  Sugita, Sunao ^a   Yamada, Yukiko ^a   Mochizuki, Manabu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEHCET DISEASE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; JAPAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS, ANTERIOR;

EID: 79952951363     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.174888     Document Type: Article

References (20)

1. Sakane T, Suzuki N, Nagafuchi H. Etiopathology of Behçet's disease: immunological aspects. Yonsei Med J 1997;38:350-8. (Pubitemid 128516394)
2. Takeuchi M, Hokama H, Tsukahara R, et al. Risk and prognostic factors of poor visual outcome in Behçet's disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol 2005;243:1147-52. (Pubitemid 43124166)
3. Mochizuki M. Immunotherapy for Behçet's disease. Int Rev Immunol 1997;14:49-66.
4. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7. (Pubitemid 24317633)
5. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
6. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
7. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-8. (Pubitemid 38879203)
8. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001;358:295-6. (Pubitemid 32738970)
9. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al. Effect of infliximab on threatening panuveitis in Behçet's disease. Lancet 2001;358:1644. (Pubitemid 33101925)
10. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 2005;52:2478-84. (Pubitemid 41117435)
11. Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol 2007;51:191-6. (Pubitemid 46889493)
12. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology (Oxford) 2007;46:1161-4. (Pubitemid 47050622)
13. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol 2008;146:845-50.
14. Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Behçet's disease. Br J Ophthalmol 2010;94:284-8.
15. Gul A. Standard and novel therapeutic approaches to Behçet's disease. Drugs 2007;67:2013-22. (Pubitemid 47524563)
16. Behçet's Disease Research Committee of Japan. Behçet's disease: guide to diagnosis of Behçet's disease. Jpn J Ophthalmol 1974;18:291-4.
17. Mizushima Y. Recent research into Behçet's disease in Japan. Int J Tissue React 1988;10:59-65.
18. Siegel SA, Shealy DJ, Nakada MT, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995;7:15-25.
19. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451-9. (Pubitemid 34620190)
20. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63. (Pubitemid 28459913)